-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

702.O3.6 702. CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells

Symposia: CAR-T Cell Therapies: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Adult, Lymphoid Leukemias, ALL, Hodgkin lymphoma, Translational Research, Non-Hodgkin lymphoma, Lymphomas, CLL, Drug development, Elderly, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, LGL, Genomics, Diversity, Equity, and Inclusion (DEI), T Cell lymphoma, Hematopoiesis, Pediatric, Diseases, Immune mechanism, Indolent lymphoma, Treatment Considerations, Biological therapies, Immunology, Aggressive lymphoma, Immunotherapy, Lymphoid Malignancies, Metabolism, Young adult , Biological Processes, Monoclonal Antibody Therapy, Molecular biology, Study Population, Human
Monday, December 9, 2024: 4:30 PM-6:00 PM
Room 6CF (San Diego Convention Center)
Moderators:
Franziska Blaeschke, MD, PhD, German Cancer Research Center and Sarah Tettamanti, PhD, Fondazione IRCCS San Gerardo dei Tintori
Disclosures:
No relevant conflicts of interest to declare.

This session will highlight new CAR T cell targets and innovative strategies to augment CAR T cell  response.
4:30 PM

Zhiwei Ang, PhD1*, Castro Annette1*, Carolin Schimdt1*, Katharina Hayer2*, Zainul S. Hasanali, MD, PhD3, Manuel Torres-Diz, PhD1*, Patricia King Sainos4*, Christopher Kwok4*, Kayla Ji4*, Patrick Krohl5*, Justyn Fine5*, Priyanka Sehgal1*, Dan Martinez6*, Dan T. Vogl, MD, MS3, Jamie B. Spangler5*, David Allman, PhD7* and Andrei Thomas-Tikhonenko, PhD1,7

1Division of Cancer Pathobiology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
2Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA
3Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
4Department of Biology, College of Arts and Sciences, University of Pennsylvania, Philadelphia, PA
5Department of Biomedical Engineering, Johns Hopkins University, Baltimore
6Pathology Core, Children's Hospital of Philadelphia, Philadelphia, PA
7Department of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

4:45 PM

Ane Altuna Mongelos1,2,3*, Lorena Perez Amill, PhD1,2,4*, Maria Val-Casals, PhD1,2,4*, Sergio Peña1,2,4*, Mercedes Armand-Ugon, PhD1,2,4*, Jose Ramón Álamo Moreno, MD5*, Juan Gonzalo Correa, MD6*, Alvaro Urbano-Ispizua, MD, PhD4,6,7, Julio Delgado, MD, PhD4,7,8*, Claudio Santos, PhD2*, Manel Juan, MD, PhD1,2,4,7* and Nela Klein-Gonzalez, MD, PhD1,2,4*

1Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain
2Gyala Therapeutics S.L., Barcelona, Spain
3Fundació de Recerca Clínic Barcelona-Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, AL, Spain
4Fundació de Recerca Clínic Barcelona-Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
5Hematopathology Section, Pathology Department, CDB, Hospital Clínic de Barcelona, Barcelona, Spain
6Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain
7University of Barcelona, Barcelona, Spain
8Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Barcelona, Spain

5:00 PM

Kunho Chung, PhD1, Dongxu Jiang, PhD2, Xiaorong Gu, PhD1*, Jie Xu, MD, PhD3, Céline Grégoire, MD, PhD1*, Beatriz Coutinho De Oliveira, PhD1, Babal Kant Jha, PhD1* and J. Joseph Melenhorst, PhD1

1Center for Immunotherapy and Precision Immuno-Oncology, Cell Therapy & Immuno-Engineering Program, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
2Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
3Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

5:15 PM

Taylor K Mandeville, BA1,2*, Jacob P Wright3*, Cory Mavis, MSc2*, Matthew J. Cortese, MD, MPH, MD, MPH4, Spencer Rosario, PhD5*, Scott Olejniczak, PhD1* and Francisco Hernandez-Ilizaliturri, MD6,7

1Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
2Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
3Department of Biological Sciences, State University of New York (University at Buffalo), Buffalo, NY
4Department of Medicine - Lymphoma Section, Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
5Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
6Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY
7Department of Medicine (Lymphoma Section), Roswell Park Comprehensive Cancer Center, Buffalo, NY

5:30 PM

Jaap A. van Doesum1*, Kylie Keijzer1,2*, Janneke W. De Boer, MD1*, Nienke A.M. Smit1*, Adrienne H. Brouwers3*, Marjolijn N. Lub-de Hooge4*, Frank R. Pierik4*, Gerwin A. Huls1, Lisanne V. van Dijk2*, Lydia Visser5*, Arjan Diepstra5, Walter Noordzij3*, Simon P. Williams6*, Alexander Ungewickell6, Sjoerd G. Elias7*, Elisabeth G.E. de Vries8*, Anne G.H. Niezink2* and Tom van Meerten1*

1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
2Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
3Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
4Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
5Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
6Genentech Inc., South San Francisco, CA
7Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
8Department of Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

5:45 PM

Hiroyuki Takamatsu, MD, PhD1,2, Emilio Ramos, MD, PhD2, Bonell Patino-Escobar, MD2*, Corynn Kasap, MD, PhD2,3, Adila Izgutdina, MD2*, Juwita Werner, MD4*, Akihito Inagaki, PhD5*, Takeshi Yoroidaka, MD, PhD1*, Fernando Salangsang6*, Paul Phojanakong, BA6*, Juan Antonio Camara Serrano, PhD6*, Veronica Steri, PhD6*, Elliot Stieglitz, MD, PhD7, Masaki Nagato, MS8*, Satoshi Tatsuno, PhD8* and Arun P Wiita, MD, PhD9

1Department of Hematology, Kanazawa University, Kanazawa, Japan
2Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
3Department of Medicine, Division of Hematology Oncology, University of California San Francisco, San Francisco, CA
4Department of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA
5Department of Neurological Surgery, University of California San Francisco, San Francisco, CA
6Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
7Division of Hematology-Oncology, Dept. of Pediatrics, University of California San Francisco Benioff Children’s Hospital, San Francisco, CA
8Molecular Diagnostics Division, Wakunaga Pharmaceutical, Hiroshima, Japan
9Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA

*signifies non-member of ASH